We are live on ! Find out more
CG

Carlyle Group Portfolio holdings

AUM $10.6B
1-Year Est. Return 11.25%
This Fund
S&P 500
This Quarter Est. Return
+5.93%
1 Year Est. Return
+11.25%
3 Year Est. Return
-0.47%
5 Year Est. Return
-4.92%
10 Year Est. Return
+7.54%
AUM
$2.08B
AUM Growth
-$226M
Cap. Flow
-$304M
Cap. Flow %
-14.63%
Top 10 Hldgs %
96.3%
Holding
26
New
1
Increased
2
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$16.1M
2
SPWR icon
SunPower Inc
SPWR
+$338K
3
SYRE icon
Spyre Therapeutics
SYRE
+$133K

Top Sells

Rank Stock Value
1
MKSI icon
MKS Inc
MKSI
+$301M
2
GTM
ZoomInfo Technologies
GTM
+$17.8M
3
GETY icon
Getty Images
GETY
+$1.65M

Sector Composition

Rank Sector Weight
1 Healthcare 57.36%
2 Technology 33.33%
3 Consumer Staples 4.75%
4 Communication Services 2.37%
5 Real Estate 1.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
1
QuidelOrtho
QDEL
$1.19B
$918M 44.17%
12,460,183
– –
GTM
2
ZoomInfo Technologies
GTM
$905M
$652M 31.34%
35,244,474
-1,132,819
-3% -$17.8M
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
$115M 5.53%
2,857,804
+564,242
+25% +$16.1M
VTRU
4
DELISTED
Vitru Limited Common Shares
VTRU
$98.4M 4.73%
6,246,471
– –
GETY icon
5
Getty Images
GETY
$216M
$49.3M 2.37%
9,394,319
-327,927
-3% -$1.65M
VRNA
6
DELISTED
Verona Pharma
VRNA
$48.8M 2.35%
2,457,500
– –
GDS icon
7
GDS Holdings
GDS
$6.24B
$37.1M 1.79%
4,072,624
– –
PHAT icon
8
Phathom Pharmaceuticals
PHAT
$873M
$31.9M 1.54%
3,496,808
– –
HLVX
9
DELISTED
HilleVax
HLVX
$29.5M 1.42%
1,838,486
– –
VERA icon
10
Vera Therapeutics
VERA
$2.76B
$22.1M 1.06%
1,438,155
– –
SMHI icon
11
SEACOR Marine Holdings
SMHI
$214M
$16.5M 0.8%
1,314,164
– –
INVH icon
12
Invitation Homes
INVH
$17.9B
$16.3M 0.78%
477,500
– –
CUBE icon
13
CubeSmart
CUBE
$9.48B
$10.2M 0.49%
220,500
– –
SPRB
14
Spruce Biosciences
SPRB
$120M
$8.37M 0.4%
38,620
– –
JSPR icon
15
Jasper Therapeutics
JSPR
$24.8M
$6.67M 0.32%
876,189
– –
OKUR
16
OnKure Therapeutics
OKUR
$170M
$4.32M 0.21%
269,896
– –
SPWR icon
17
SunPower Inc
SPWR
$102M
$4.26M 0.2%
2,745,879
+250,000
+10% +$338K
ACET icon
18
Adicet Bio
ACET
$75.9M
$3.98M 0.19%
132,212
– –
EM
19
DELISTED
Smart Share Global Ltd
EM
$2.41M 0.12%
4,810,209
– –
EFTR
20
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$2.23M 0.11%
192,885
– –
NCNA
21
NuCana
NCNA
$5.45M
$967K 0.05%
667
– –
AIU
22
DELISTED
Meta Data Limited American Depositary Shares, each representing ten (10) Class A Ordinary Shares
AIU
$306K 0.01%
62,880
– –
SYRE icon
23
Spyre Therapeutics
SYRE
$8.7B
$204K 0.01%
+9,620
New +$133K
XCUR icon
24
Exicure
XCUR
$10.7M
$163K 0.01%
56,327
– –
MTEM
25
DELISTED
Molecular Templates, Inc.
MTEM
$49.3K ﹤0.01%
13,333
– –
1
2

Similar funds

SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $10.8B AUM 21.99% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $10.9B AUM 18.64% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

Carlyle Group's Q4 2023 Portfolio in Review

As of Q4 2023, Carlyle Group held 26 positions worth $2.08B, down 9.8% from $2.31B the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Carlyle Group withdrew a net $304M in Q4 2023, closing 1 position and reducing 2 holdings. Its most notable exit was MKS Inc, an estimated $301M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 49% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Carlyle Group opened a new position in Spyre Therapeutics worth $204K.

  • Carlyle Group's largest Q4 2023 buy was Spyre Therapeutics: 9,620 shares worth $204K.
  • Carlyle Group added most to Soleno Therapeutics in Q4 2023, an estimated $16.1M increase.
  • Carlyle Group's biggest Q4 2023 reduction was ZoomInfo Technologies, cutting an estimated $17.8M.
  • Carlyle Group fully exited MKS Inc in Q4 2023, selling an estimated $301M.
  • Carlyle Group's ten largest holdings make up 96% of its $2.08B portfolio in Q4 2023.
  • Carlyle Group opened 1 new position and closed 1 in Q4 2023.
  • Carlyle Group's portfolio value fell 9.8% quarter-over-quarter to $2.08B.

Based on Carlyle Group's 13F filing for Q4 2023, filed 2 Feb 2024.